Fig. 5

The m6Ascore subtypes guided chemotherapy strategies and immune landscape evaluation. A Boxviolins for estimated IC50 of Cisplatin and Paclitaxel among 4 identified m6Ascore subtypes in TCGA-THCA cohort. *p <0.05; **p <0.01; ****p <0.0001; B The RNA expression of eight CD8+ T cell effector genes in m6Ascore-mc3 and mc124 groups; C The immune checkpoint gene expression levels in m6Ascore-mc3 and mc124 groups; D The signature fibroblast, Treg and T cells regulatory score of immune suppression in m6Ascore-mc3 and mc124 groups; E The difference of the tumor immune dysfunction and exclusion score between the m6Ascore-mc3 and mc124 groups